185 related articles for article (PubMed ID: 34435697)
1. Refractory serum immunoglobulin M elevation during anti-interleukin (IL)-1- or IL-6-targeted treatment in four patients with Schnitzler syndrome.
Takimoto-Ito R; Kambe N; Kogame T; Otsuka A; Nomura T; Izawa K; Tabuchi Y; Yoshifuji H; Takeuchi Y; Kabashima K
J Dermatol; 2021 Nov; 48(11):1789-1792. PubMed ID: 34435697
[TBL] [Abstract][Full Text] [Related]
2. Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab.
Salcedo-Mingoarranz AL; Dorado-Fernández M; García-Martínez S; Collado-Ramos P; Silvestre-Torner N
J Dermatolog Treat; 2023 Dec; 34(1):2242705. PubMed ID: 37551725
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.
Rowczenio DM; Pathak S; Arostegui JI; Mensa-Vilaro A; Omoyinmi E; Brogan P; Lipsker D; Scambler T; Owen R; Trojer H; Baginska A; Gillmore JD; Wechalekar AD; Lane T; Williams R; Youngstein T; Hawkins PN; Savic S; Lachmann HJ
Blood; 2018 Mar; 131(9):974-981. PubMed ID: 29284595
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 receptor antagonist (anakinra) for Schnitzler syndrome.
Sönnichsen A; Saulite I; Mangana J; Kerl K; Mehra T; Desislava I; Chang YT; Petrausch U; Schmid-Grendelmeier P; Hoetzenecker W; Cozzio A; Guenova E
J Dermatolog Treat; 2016 Oct; 27(5):436-8. PubMed ID: 26864191
[TBL] [Abstract][Full Text] [Related]
5. Schnitzler Syndrome: Insights into Its Pathogenesis, Clinical Manifestations, and Current Management.
Braud A; Lipsker D
Biomolecules; 2024 May; 14(6):. PubMed ID: 38927050
[TBL] [Abstract][Full Text] [Related]
6. Case report: Schnitzler-like syndrome without monoclonal gammopathy.
Wesselmann AS; Künstner A; Fähnrich A; Rose C; Lamprecht P; Busch H; Ludwig RJ; Recke A
Front Immunol; 2023; 14():1166620. PubMed ID: 37063861
[TBL] [Abstract][Full Text] [Related]
7. Schnitzler Syndrome Without a Monoclonal Gammopathy: A Case Report.
Urbanski M; Holfeld K; Milne A; Abbas M
J Cutan Med Surg; 2016 Nov; 20(6):575-578. PubMed ID: 27358310
[TBL] [Abstract][Full Text] [Related]
8. Similarities and differences in autoinflammatory diseases with urticarial rash, cryopyrin-associated periodic syndrome and Schnitzler syndrome.
Matsuda T; Takimoto-Ito R; Lipsker D; Kambe N
Allergol Int; 2023 Jul; 72(3):385-393. PubMed ID: 36906447
[TBL] [Abstract][Full Text] [Related]
9. An unusual presentation of immunoglobulin A gammopathy in a patient with Schnitzler's syndrome.
Kaganov E; Jhaveri D; Peters P; IJdo JW
Int J Rheum Dis; 2023 Oct; 26(10):2085-2088. PubMed ID: 37191194
[TBL] [Abstract][Full Text] [Related]
10. [Schnitzler syndrome: diagnostics and treatment].
Szturz P; Adam Z; Sedivá A; Fojtík Z; Corbová D; Neubauer J; Prásek J; Hájek R; Mayer J
Klin Onkol; 2011; 24(4):271-7. PubMed ID: 21905617
[TBL] [Abstract][Full Text] [Related]
11. [Schnitzler syndrome].
Gellrich FF; Günther C
Hautarzt; 2018 Sep; 69(9):761-772. PubMed ID: 30167710
[TBL] [Abstract][Full Text] [Related]
12. Canakinumab in Schnitzler syndrome.
Vanderschueren S; Knockaert D
Semin Arthritis Rheum; 2013 Feb; 42(4):413-6. PubMed ID: 22901459
[TBL] [Abstract][Full Text] [Related]
13. [Schnitzler syndrome: case report, the experience with glucocorticoid and anakinra (Kineret) therapies and monitoring of systemic cytokine response].
Szturz P; Adam Z; Klabusay M; Fojtík Z; Kadanka Z; Stehlíková O; Chovancová J; Kalvodová L; Corbová D; Starý K; Neubauer J; Prásek J; Koukalová R; Rehák Z; Hájek R; Mayer J
Vnitr Lek; 2011 Jan; 57(1):97-112. PubMed ID: 21351669
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review.
Betrains A; Staels F; Vanderschueren S
Semin Arthritis Rheum; 2020 Aug; 50(4):636-642. PubMed ID: 32502728
[TBL] [Abstract][Full Text] [Related]
15. A patient with urticarial lesions, recurrent fever, and IgM-type monoclonal gammopathy.
Kecelj Žgank B; Benko M
Acta Dermatovenerol Alp Pannonica Adriat; 2022 Mar; 31(Suppl):S27-S29. PubMed ID: 35339140
[TBL] [Abstract][Full Text] [Related]
16. Schnitzler Syndrome: the paradigm of an acquired adult-onset auto-inflammatory disease.
Gusdorf L; Lipsker D
G Ital Dermatol Venereol; 2020 Oct; 155(5):567-573. PubMed ID: 33295738
[TBL] [Abstract][Full Text] [Related]
17. Schnitzler syndrome and Schnitzler-like syndromes.
Chu CQ
Chin Med J (Engl); 2022 May; 135(10):1190-1202. PubMed ID: 35089885
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study.
Krause K; Tsianakas A; Wagner N; Fischer J; Weller K; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2017 Apr; 139(4):1311-1320. PubMed ID: 27658762
[TBL] [Abstract][Full Text] [Related]
19. [Anakinra treatment in Schnitzler syndrome - results of the first retrospective multicenter study in six patients from the Czech Republic].
Szturz P; Sedivá A; Zurek M; Adam Z; Stork J; Cermáková Z; Steyerová P; Vokáčová A; Hrbek J; Sýkora M; Spička I; Mechl Z; Mayer J
Klin Onkol; 2014; 27(2):111-26. PubMed ID: 24739048
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome.
Huang Y; Wang Y; Yu F; Mao X; Wang B; Li J; Li L
Front Immunol; 2022; 13():894464. PubMed ID: 35514998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
